We computed the transcriptomic score including the top 9 upregulated genes in prostate tumor tissues with Emerin pauperization in the NE and EMD-KO experiments (CXCR4, APOE, SPARC, VIM, GSN, ANXA2P2, SFRP1, COL18A1, and FN1), and compared it with the patients’ clinical characteristics and disease-free survival (DFS) time, defined as the time to disease recurrence or progression. This evidence concerns the gene ANXA2P2 and prostate neoplasm.